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Clinical importance of epicardial adipose tissue
Eszter Nagy, Adam L. Jermendy, Bela Merkely, Pal Maurovich-Horvat
A b s t r a c t
Different visceral fat compartments have several systemic effects and may 
play a role in the development of both insulin resistance and cardiovascu-
lar diseases. In the last couple of years special attention has been paid to 
the epicardial adipose tissue (EAT), which can be quantified by non-invasive 
cardiac imaging techniques. The epicardial fat is a unique fat compartment 
between the myocardium and the visceral pericardium sharing a  common 
embryologic origin with the visceral fat depot. Epicardial adipose tissue has 
several specific roles, and its local effects on cardiac function are incorpo-
rated in the complex pathomechanism of coronary artery disease. Impor-
tantly, EAT may produce several adipocytokines and chemokines that may 
influence – through paracrine and vasocrine effects – the development and 
progression of coronary atherosclerosis. Epicardial adipose tissue volume 
has a  relatively strong genetic dependence, similarly to other visceral fat 
depots. In this article, the anatomical and physiological as well as patho-
physiological characteristics of the epicardial fat compartment are reviewed.
Key words: coronary artery disease, epicardial adipose tissue, insulin 
resistance syndrome, visceral fat compartments, epicardial fat.
Introduction
Type 2 diabetes mellitus due to its prevalence rate and cardiovascular 
complications carries a serious burden for health care systems worldwide 
[1]. Insulin resistance syndrome with the dysfunction of the abdominal 
fat compartment plays an important role in the disease development [2, 
3]. In the last couple of years it was documented that other fat compart-
ments may also be involved in the insulin resistance syndrome and may 
contribute to the pathogenesis of atherosclerosis [4]. Recently, special 
attention has been paid to the epicardial fat compartment [5].
In the 19th century it was believed that fatty degeneration of the heart 
is the main cause of every heart disease [6]. Richard Quain was the most 
well-known proponent of this theory, recognizing the relationship of in-
creased fat volume on the epicardial surface with coronary artery ob-
struction. The diagnosis of fatty heart was very popular in the Victorian 
era but was later changed to fibrosus heart disease and chronic myo-
carditis. All these diagnoses were replaced by the ischemia theory in the 
middle of the 20th century. Interestingly, it was recognized at that time 
that 70% of the fatty heart diagnoses in Quain’s pathological records 
corresponded with ischemic heart disease. Although the relationship be-
tween increased epicardial fat and cardiac diseases was described near-
ly 150 years ago, medicine did not dedicate too much attention to this 
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field. However, cardiovascular research has begun 
to explore the role of different fat compartments 
in line with the pandemic spread of obesity and 
the dynamic development of radiological imaging 
techniques [7]. In this regard, special attention 
was paid to the epicardial fat due to its anatomi-
cal proximity with the coronary arteries [8]. While 
anatomical and biochemical characteristics of 
the epicardial fat compartment were described in 
early studies, its potential role in the pathomech-
anism of coronary artery disease (CAD) and other 
cardiac dysfunctions has only been investigated 
recently.
In this article, the anatomical and physiologi-
cal as well as pathophysiological characteristics of 
the epicardial fat compartment are reviewed. 
Terminology
The terminology of fat compartments around 
the heart is not standardized; there are still many 
imprecise uses of these definitions in the litera-
ture. Nevertheless, the most widely used and ac-
cepted terms are summarized in Table I. 
The epicardial fat as a part of the visceral fat is 
localized between the myocardial surface and the 
visceral layer of the pericardium. Pericardial fat in-
volves adipose tissues between the two (visceral 
and parietal) pericardial layers and the fat depot 
on the external surface of the parietal pericardi-
um. Paracardial fat contains fat deposits outside 
the parietal pericardium and therefore sometimes 
is called extra-pericardial intrathoracic fat. The 
coronary arteries are surrounded by the perivas-
cular/pericoronary fat, irrespective of location. 
The term ectopic fat implies triglyceride deposits 
in non-adipose tissue of different organs such as 
myocardium, liver, pancreas, etc. [9].
The clear distinction of epicardial fat from peri-
cardial fat is of great clinical importance [10]. In 
the embryological aspect they differ from each 
other. While the epicardial fat is similar to the vis-
ceral fat and originates from mesodermal cells, 
the pericardial fat has an ectodermal origin, sim-
ilar to subcutaneous fat. Moreover, there is also 
a  difference in the blood supply between these 
two fat compartments; the epicardial fat is sup-
plied by the small myocardial coronary arteries, 
while the circulation of pericardial fat is provided 
from the thoracic vessels. The amount of epicardi-
al and pericardial fat compartments as a percent-
age of total cardiac mass also differs (Table II).
Cardiac imaging of epicardial adipose tissue
Epicardial fat tissue can be visualized and 
quantified non-invasively by echocardiography, 
magnetic resonance imaging (MRI) and cardiac 
computed tomography (CT). 
Echocardiography provides a simple, cheap and 
readily available assessment which directly pic-
tures the epicardial adipose tissue (EAT) thickness 
on the free wall of the right ventricle. Imaging by 
echocardiography provides the parasternal short- 
and long-axis view in three consecutive end-sys-
tolic phases (Figure 1). Several studies have estab-
Table I. Terminology of fat compartments around the heart
Visceral fat Adipose tissue around the visceral organs
Epicardial fat Visceral fat between the myocardial surface and the visceral layer  
of the pericardium
Pericardial fat Adipose tissue between the two pericardial layers (visceral and parietal 
pericardium) and fat depot on the external surface of the parietal pericardium
Paracardial fat Fat deposits outside the parietal pericardium (extra-pericardial thoracic fat)
Perivascular (pericoronary) fat Adipose tissue around the vessels (coronary arteries) irrespective of location
Ectopic fat Lipid (triglycerides) deposits in non-adipose tissue (i.e. myocardium, liver, 
pancreas, etc.)
Table II. Differences between epicardial and pericardial fat compartments
Variable Epicardial fat Pericardial fat
Location Between the myocardial surface and  
the visceral pericardium
Outside the visceral pericardium, between 
the visceral and parietal pericardium and 
on the external surface of the parietal 
pericardium
Embryologic origin Splanchnopleuric mesoderm Primitive thoracic mesenchyme
Blood supply Branches from the coronary arteries Non-coronary sources (branches from the 
internal mammary artery)
Amount 20% of total heart weight 20–40% of cardiac mass
Eszter Nagy, Adam L. Jermendy, Bela Merkely, Pal Maurovich-Horvat
866 Arch Med Sci 4, June / 2017
lished the general EAT thickness under 7 mm in 
the asymptomatic population [11]. Nevertheless, 
this method has several disadvantages includ-
ing poor reproducibility and high dependence on 
the observer’s experience. In addition, it may not 
reflect accurately the whole quantity of the epi-
cardial fat due to the two-dimensional nature of 
the measurement. In other words, the thickness 
rather than the entire quantity of the pericardial 
fat compartment can be assessed by echocardiog-
raphy. Moreover, the method has poor intra- and 
interobserver variability, and its results may differ 
significantly from the measurements with CT [12]. 
In contrast to echocardiography, MRI provides 
accurate area measurements with enhanced spin-
echo sequence and, in this way, EAT area mass 
and volume can be calculated (Figure 2). Area 
measurements with MRI correspond well with fat 
thickness determination with echocardiography, 
although the Bland-Altman analysis shows a sys-
temic bias through overestimation of EAT with 
echocardiography [13]. Magnetic resonance imag-
ing is hardly available in routine clinical practice, is 
more expensive and has poorer spatial resolution 
compared to CT. 
True volume assessment of EAT is feasible us-
ing cardiac CT. The three dimensional (3D) image 
reconstruction with multidetector-row CT (MDCT) 
has the best spatial resolution among the im-
aging modalities (Figure 3). It is of note that the 
specificity and sensitivity of measurements with 
MDCT are the best when compared to alternative 
imaging methods. The epicardial fat quantifica-
tion is performed on prospectively ECG triggered 
non-contrast CT scans which extend from the 
pulmonary artery bifurcation to the diaphragm. 
The identification of the EAT is based on thresh-
olds of CT attenuation. Typically, lower thresh-
olds of CT attenuation range from –250 to –190 
Hounsfield units (HU), and upper thresholds are 
Figure 1. Quantification of epicardial adipose tis-
sue by echocardiography (parasternal view). The 
thickness of the area between the myocardium 
and the visceral layer of the pericardium is 0.85 cm, 
indicating epicardial adipose tissue
Figure 2. Epicardial adipose tissue (arrow) by using 
magnetic resonance imaging (MRI) technique
RA – right atrium, LA – left atrium, RV – right ventricle, 
LV – left ventricle.
Figure 3. Measuring epicardial adipose tissue by cardiac computed tomography (CT). A – Axial section at the aortic 
root. Arrows indicate the visceral layer of the pericardium. Epicardial fat (E) is located inside and pericardial fat (P) 
outside the visceral layer. B – The visceral layer of the pericardium is traced manually (green). Epicardial adipose 
tissue (yellow) is marked automatically at the corresponding section. C – Three-dimensional reconstruction of the 
total epicardial fat compartment (yellow). The volume of epicardial adipose tissue was 112 cm3
CBA
Clinical importance of epicardial adipose tissue
Arch Med Sci 4, June / 2017 867
set between –50 and –30 HU. In contrast to area 
and thickness measurements, volume quantifica-
tion provides the most accurate way for assess-
ing the true epicardial fat quantity [14]. Using this 
method, coronary artery calcification may also 
be quantified, resulting in more reliable cardio-
vascular risk assessment [15]. Importantly, native 
CT results in a very small (1 mSv) radiation dose. 
Maurovich-Horvat et al. found in a  collaborative 
study that the measurement of pericoronary adi-
pose tissue was highly reproducible when using 
MDCT [16]. 
Anatomical characteristics of epicardial 
adipose tissue
In physiological circumstances the epicardial 
fat covers nearly 80% of the heart surface. Accord-
ing to previous observations this fat compartment 
contributes 20% to the whole heart quantity [17]. 
The EAT-covered heart region includes the heart 
base and the apex, the atrioventricular sulci, the 
entire surface of the right ventricle, and the great 
coronary vessels with their origins. The distribu-
tion of EAT is mostly inhomogeneous; the biggest 
mass is localized on the lateral and anterior walls 
of the right atrium, but in normal circumstances 
it also covers the atrioventricular and the inter-
ventricular sulci and the main coronary arteries as 
well. In the case of extremely enlarged EAT, it can 
also accumulate on the surface of the left atrium 
and along the vessel’s adventitia with spreading 
into the myocardium. It is of note that there is no 
separating fascia layer between the epicardial fat 
and the myocardium, providing close proximity 
of these two different tissues [18]. In histological 
investigations it has been previously established 
that adipocytes in the EAT are smaller than those 
in the abdominal or the subcutaneous fat com-
partments [19]. Besides adipocytes, EAT includes 
nerves, ganglions, vessels, inflammatory cells and 
fibrocytes as well (Figure 4).
Age, gender, body weight and ethnicity should 
be taken into consideration among physiologi-
cal determinants of EAT. Epicardial adipose tissue 
seems to increase with age [20]. The quantity of 
EAT depends on gender and body mass index 
(BMI). For example, pericardial fat was reported 
to be 137 ±54 cm3 among men and 108 ±41 cm3 
among women of the Framingham offspring cohort 
[21]. In patients with a high BMI (> 27 kg/m2), EAT 
volume was more than two times higher compared 
to those with a BMI < 27 kg/m2 (155 ±15 cm3 vs. 
67 ±12 cm3) [22]. Some ethnic differences in epicar-
dial and pericardial fat thickness may also occur; 
non-Hispanic White men have more epicardial and 
pericardial fat than do African Americans [23].
The biochemical features of small adipocytes 
in EAT may also differ from those of other fat 
compartments. In experimental studies EAT had 
a higher rate of free fatty acid (FFA) release than 
adipose tissue elsewhere in the body, suggesting 
that EAT might play a role in local energy supply 
for the myocardium. In addition, a lower oxidative 
capacity and a  lower rate of glucose utilization 
were also documented [24]. On the other hand, 
a 5-fold higher expression of uncoupled protein-1 
(UCP-1) was found in EAT compared to other fat 
depots [25]. Uncoupled protein-1 is a specific pro-
tein in brown fat which is necessary for its energy 
production, and does not appear in other types of 
fat tissues. This latter feature is in line with the 
fact that epicardial fat evolves from brown adi-
pose tissue during embryogenesis. 
Physiological function of epicardial adipose 
tissue
Several physiological functions of EAT are al-
ready known from different studies or inferred 
from its biochemical or anatomical features. Unfor-
tunately, experimental evidence supporting these 
observations are limited due to the very small 
amount of EAT in experimental animals (rodents). 
It is suggested that functions of EAT may in-
clude protection of the myocardium against hypo-
thermia [25]. In addition, EAT can provide a me-
chanical protective role for coronary circulation. It 
can attenuate the torsion developed by the myo-
cardium contraction or the arterial pulse wave, 
but it has a permissive role as well in positive re-
modeling of coronary arteries [26]. 
Figure 4. Microscopic view of the epicardial adi-
pose tissue. It is of note that there is no separat-
ing fascia layer between the epicardial fat and the 
myocardium
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Also, EAT has a substantial role in energy supply 
to the myocardium and should be considered as 
a provider of energy during periods of high energy 
demand [27]. On the other hand, EAT may protect 
the myocardium from the cardiotoxic effect of 
a large amount of FFA due to its capacity for fast 
FFA utilization [28]. Taken together, EAT may serve 
as a unique energy buffering pool in the homeo-
stasis of the myocardium.
In addition, adiponectin secretion from epicar-
dial adipocytes may promote the coronary circu-
lation. Adiponectin improves endothelial func-
tion through stimulation of nitrogen monoxide 
synthase, reduces oxidative stress, and indirectly 
decreases the level of interleukin-6 (IL-6) and C-re-
active protein (CRP) by reducing tumor necrosis 
factor-α (TNF-α) production [29, 30]. Adiponec-
tin also has some extracardial effects such as in-
creased glucose utilization in the hepatocytes and 
muscle cells which may result in improving insulin 
sensitivity [31]. 
Epicardial adipose tissue in the 
pathomechanism of atherosclerosis 
Some years ago a hypothesis about the direct 
role of EAT in the development and progression 
of coronary atherosclerosis was raised, and para-
crine and vasocrine effects of EAT due to close 
proximity of epicardial fat to coronary arteries 
were posited [32]. The hypothesis was indirectly 
supported by a pathological study in subjects with 
a  myocardial bridge. Namely, no atherosclerosis 
was observed in coronary segments at the myo-
cardial bridge where surrounding fat on the coro-
nary arteries was lacking [33]. 
In a  landmark study, Mazurek et al. analyzed 
epicardial and subcutaneous fat from the lower 
extremity in obese patients referred for coronary 
artery bypass grafting. They found increased lev-
els of inflammatory mediators (IL-6, TNF-α, inter-
leukin-1β (IL-1β), monocyte chemoattractant pro-
tein-1 (MCP-1)), macrophages, lymphocytes and 
basophils in epicardial fat as compared to subcu-
taneous fat compartments [34]. Others found that 
epicardial and omental fat exhibited a  broadly 
comparable pathogenic messenger ribonucleo-
tide acid (mRNA) profile indicating macrophage 
infiltration into the epicardial fat [35]. In another 
study, mediators of the nuclear factor-kB (NF-kB) 
and c-Jun N-terminal kinase (JNK) pathways were 
suggested to be involved in the inflammatory 
profile of EAT, highlighting the role of the macro-
phages in the inflammation within this tissue [36]. 
These studies indicate that chronic inflammation 
occurs locally as well as systemically, potentially 
contributing further to the pathogenesis of CAD. 
It was documented that the epicardial adipo-
cytes had impaired adiponectin secretion and in-
creased leptin production in obese patients with 
hypertension, metabolic syndrome and CAD [37, 
38]. This shift in the adiponectin/leptin ratio en-
hances the development of atherosclerosis. Namely, 
the decreased adiponectin expression attenuates 
endothelial function and leads to increased TNF-α 
production, triggering systematic inflammation and 
oxidative stress. The altered leptin level promotes 
atherogenic changes in endothelial cells such as 
increased adhesion of monocytes, a higher level of 
macrophage-to-foam cell transformation, unfavor-
able changes in lipid levels, and elevation of CRP 
and inflammatory cytokine levels. All these alter-
ations may lead to development and destabilization 
of atherosclerotic plaques in coronary arteries [5].
Based on several studies it became widely ac-
cepted that EAT should be considered as a source 
of inflammatory mediators that might directly 
influence the myocardium and coronary arteries 
(Figure 5). Two mechanisms of influence (paracrine 
Figure 5. Routes for paracrine and vasocrine effects of epicardial adipose tissue on coronary arteries and plaque 
formation
IL – interleukin, TNF-α – tumor necrosis factor-α, MCP-1 – monocyte chemoattractant protein-1, PAI-1 – plasminogen activator 
inhibitor-1, VEGF – vascular endothelial growth factor.
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and vasocrine) were suggested [39]. The paracrine 
way of influence means that adipokines released 
from pericoronary fat may diffuse across the arte-
rial wall (adventitia, media, and intima) and final-
ly can interact with endothelial cells in the intima 
and with vascular smooth cells in the media. The 
alternative vasocrine way of effect can be achieved 
by release of adipocytokines and FFAs from EAT di-
rectly into the vasa vasorum of the coronary arte-
rial wall [40]. It was suggested that the vasocrine 
way of influence may be predominant over the 
paracrine effect in the case of more advanced ath-
erosclerotic lesions where inflammatory mediators 
may diffuse only with difficulties [35]. 
The association between EAT thickness and the 
metabolic syndrome was documented in a recent 
meta-analysis [41]. The relationship of EAT with 
CAD has been analyzed by several clinical studies 
[42, 43]. In the Framingham and the MESA (Mul-
tiethnic Study of Atherosclerosis) epidemiologi-
cal studies a significant association of epicardial 
fat with coronary artery calcification was found, 
which remained significant after adjustment for 
traditional cardiovascular risk factors [44, 45]. The 
increased epicardial fat proved to be associated 
with more advanced atherosclerosis in anoth-
er study [46]. Epicardial fat was associated with 
non-calcified coronary plaques as well [47, 48]. 
A  significant relationship of increased epicardial 
fat volume (> 130.7 cm3) with vulnerable plaques 
was also documented [49]. The relationship of 
morphological features of vulnerable plaques 
(positive remodeling, spotty calcifications, and 
low CT attenuation in the necrotic core) to the 
pericardial fat was also studied, and the volume 
of pericardial fat proved to be nearly twice as high 
in patients with vulnerable plaques as compared 
to those without CAD [50]. Pericardial fat was as-
sociated with myocardial ischemia detected by 
single photon emission computed tomography 
(SPECT) in patients without known CAD [51]. Epi-
cardial adipose tissue correlated with the degree 
of coronary atheromatosis, suggesting that its 
excessive accumulation might contribute to the 
development of acute coronary syndrome and cor-
onary total occlusions [52]. In another study, EAT 
thickness was independently associated with the 
Thrombolysis in Myocardial Infarction (TIMI) risk 
score in patients with non-ST-elevation myocardi-
al infarction (NSTEMI) and unstable angina pecto-
ris [53]. In patients with the metabolic syndrome, 
increased EAT was associated with impaired coro-
nary flow reserve [54]. In a different patient popu-
lation (in women with chest pain and angiograph-
ically normal coronary arteries), EAT thickness was 
correlated with reduced coronary flow reserve 
[55]. Different surrogate parameters of athero-
sclerosis were also investigated by others, and an 
association between EAT thickness and carotid in-
tima-media thickness in type 2 diabetic patients 
as well as in children and adolescents with obe-
sity was found [56, 57]. Moreover, EAT showed an 
independent association with arterial stiffness in 
an asymptomatic Korean cohort [58]. In a recent 
study, Maurovich-Horvat et al. investigated the re-
lationship of different thoracic fat depots with cor-
onary atherosclerosis and found an independent 
association between pericoronary fat and CAD. In 
addition, pericoronary fat correlated with inflam-
matory biomarkers as well, suggesting that while 
systemic inflammation plays a role in the patho-
genesis of CAD, additional local effects may exist 
[59]. In a systematic review and meta-analysis, an 
association between the elevated location-spe-
cific thickness of EAT at the left atrioventricular 
groove and obstructive CAD was found [60].
Epicardial adipose tissue and other cardiac 
abnormalities
The relationship of EAT with atrial fibrillation 
was analyzed in several clinical studies. A strong 
association between EAT and atrial fibrillation 
(both paroxysmal and persistent) was document-
ed by Al Chekakie et al.; the relationship proved to 
be independent of traditional risk factors and atri-
al enlargement [61]. In another study, EAT thick-
ness was verified as an independent predictor for 
post-ablative recurrence of atrial fibrillation [62]. 
In patients with peritoneal dialysis, increased EAT 
was associated with impaired left ventricle dia-
stolic capacity independently of CRP level, a mark-
er of systemic inflammation [63].
Epicardial adipose tissue necrosis: a benign 
cause of chest pain
Epicardial fat necrosis is a  rare clinical con-
dition; 26 cases were reported up to 2011 [64]. 
It should be considered in the differential diag-
nosis of chest pain. The etiology is obscure, but 
the prognosis is good. In general, the presenting 
symptom is left-sided chest pain in a previously 
healthy individual with an associated juxtacardi-
ac mass seen in chest radiography. The CT or MRI 
may confirm the correct diagnosis, resulting in the 
avoidance of surgical intervention.
Epicardial adipose tissue in type 2 diabetes, 
obesity and the insulin resistance syndrome 
(metabolic syndrome) 
Typically, type 2 diabetes is preceded by pre-
diabetes, but insulin resistance syndrome due to 
obesity may be the first pathological stage in the 
long-lasting asymptomatic period of diabetes. The 
insulin resistance syndrome (also called the met-
abolic syndrome) includes insulin resistance and 
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different metabolic abnormalities (elevated serum 
triglycerides, lower HDL cholesterol, hyperglyce-
mia) as well as elevated blood pressure. Obesity, 
especially abdominal visceral fat accumulation, 
plays a central role in this syndrome. Although the 
use of the term and the suggested pathomecha-
nism of the metabolic syndrome became debat-
able some years ago, the association between an 
enlarged abdominal visceral fat compartment and 
increased cardiovascular risk remained unques-
tionable [65]. The enlarged visceral fat depot is 
characterized primarily by increased lipolysis lead-
ing to hepatic steatosis. Non-alcoholic fatty liver 
disease (NAFLD) is often regarded as the hepat-
ic manifestation of insulin resistance [66] and is 
considered as a novel predictor of cardiovascular 
disease [67, 68]. 
Several clinical investigations have aimed to 
assess the characteristics of EAT in the metabol-
ic syndrome, prediabetes and type 2 diabetes. In 
a meta-analysis, EAT was 7.5 ±0.1 mm in thickness 
in the metabolic syndrome (n = 427) compared to 
4.0 ±0.1 mm in controls (n = 301), and EAT cor-
related significantly with the components of the 
metabolic syndrome [69]. Epicardial adipose tis-
sue volume was significantly higher in patients 
with type 2 diabetes than in nondiabetic subjects, 
and EAT volume was significantly associated with 
components of the metabolic syndrome [46]. In as-
ymptomatic type 2 diabetic patients the thickness 
of EAT proved to be an independent risk factor for 
significant coronary artery stenosis but not for si-
lent myocardial ischemia [70]. A strong correlation 
was found between fasting plasma glucose and 
EAT measured with CT or echocardiography [71, 
72]. Epicardial adipose tissue quantity was high-
er in patients with type 2 diabetes mellitus com-
pared to lean subjects or obese patients without 
diabetes. In addition, the difference in EAT volume 
between men and women was more pronounced 
in subjects with impaired fasting glucose or dia-
betes mellitus [73]. A clear relationship of epicar-
dial fat and serum alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) activity, 
surrogate markers of fatty liver, was documented 
in a cross-sectional, observational study [74]. Tak-
en together, the insulin resistance syndrome (the 
metabolic syndrome), type 2 diabetes, NAFLD and 
CAD are associated with an increased amount of 
epicardial fat [75].
In the majority of studies an increase of EAT 
volume was associated with stenosis of the cor-
onary arteries [76, 77]. Since these studies are 
cross-sectional, it is uncertain whether adipose 
tissue plays a  causal role in the development of 
atherosclerosis. Importantly, two longitudinal 
studies have reported results that support the hy-
pothesis of ‘outside to inside signaling’ as a cause 
of atherosclerosis [45, 78]. In these studies, intra-
thoracic and EAT volume were measured and an 
increase of the quantity of intrathoracic and EAT 
was associated with incident coronary heart dis-
ease and with major adverse cardiac events. As-
sociations were independent from BMI and other 
risk factors, suggesting that EAT is one of the fac-
tors contributing to CAD.
Epicardial adipose tissue in type 1 diabetes
Interestingly, higher epicardial fat and serum 
leptin levels were found in subjects with type 1 
diabetes than in non-diabetic controls. The epicar-
dial fat thickness and serum leptin levels proved 
to be the best independent correlates of each oth-
er in patients with type 1 diabetes independently 
of BMI, glycemic control and daily insulin require-
ment [79]. Recently, patients with type 1 diabetes 
(n = 100) from the Diabetes Control and Compli-
cations Trial/Epidemiology of Diabetes Interven-
tions and Complications (DCCT/EDIC) study were 
investigated. In this pilot study, the accumulation 
of adipose tissue in epicardial and intra-thoracic 
spaces was strongly associated with higher BMI, 
greater waist-to-hip ratio, higher weighted glycat-
ed hemoglobin values, elevated triglycerides and 
a  history of elevated albumin excretion rate or 
end-stage renal disease [80].
Role of genetic effects on epicardial adipose 
tissue
As EAT and other abdominal fat compartments 
(subcutaneous adipose tissue (SAT), visceral adi-
pose tissue (VAT), hepatic lipid accumulation) car-
ry different clinical significance [81] and epicardial 
fat differs from pericardial fat from an embryolog-
ical point of view, the role of genetic effects on 
EAT and other fat compartments may differ. In 
a  classical twin study with CT investigation our 
preliminary results indicated that EAT had a rela-
tively strong genetic dependence, similarly to BMI 
and waist circumference [82, 83]. In contrast to 
abdominal fat compartment areas, a weak genet-
ic and a  stronger environmental dependence of 
hepatic lipid accumulation was found in our twin 
cohort [84]. 
Treatment options for modifying epicardial 
adipose tissue volume
Lifestyle changes, bariatric surgery and various 
drugs may be applied. Reduction in weight (BMI) 
by using a very-low calorie diet or exercise train-
ing program in obese patients is associated with 
a decrease in EAT volume [85, 86]. Nevertheless, 
this was observed after bariatric surgery as well, 
although myocardial triglyceride content did not 
change significantly [87]. In a meta-analysis, diet 
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or bariatric surgery proved to be more beneficial 
than exercise training in reducing EAT volume 
[88]. The effect of drugs on EAT is controversial. 
Atorvastatin resulted in a  more pronounced de-
crease of EAT than simvastatin/ezetimibe [89]. 
Pioglitazone compared with metformin increased 
pericardial fat volume in patients with type 2 di-
abetes [90]. Short-term (3 months) use of gluca-
gon-like-receptor agonists (exenatide, liraglutide) 
decreased the volume of EAT in type 2 diabetic 
patients [91]. In a longer (26 weeks) randomized 
controlled trial, exenatide twice daily (versus stan-
dard antidiabetic treatment) proved to be effec-
tive in reducing both epicardial and liver fat con-
tent in obese patients with type 2 diabetes; the 
effects were mainly weight loss dependent [92]. 
In another study, sitagliptin, a  dipeptidyl-pepti-
dase-4 inhibitor, also decreased the volume of EAT 
in a 24-week long study with obese type 2 diabet-
ic patients [93]. Clearly, EAT should be considered 
as a novel therapeutic target, and statins, pioglita-
zone as well as incretin-based drugs are the best 
candidates so far [94, 95]. 
Conclusions
The epicardial fat is a unique fat compartment 
located between the myocardial surface and the 
visceral layer of the pericardium. The EAT can be 
quantified by non-invasive cardiac imaging tech-
niques such as echocardiography, MRI or cardiac CT. 
Among physiological determinants of EAT, age, 
gender, body weight and ethnicity should be con-
sidered. The EAT volume has a  relatively strong 
genetic dependence, similarly to other visceral fat 
depots. Physiological functions of EAT may include 
protection of the myocardium against hypother-
mia and a mechanical protective role for coronary 
circulation. In addition, EAT may serve as a unique 
energy buffering pool in the homeostasis of the 
myocardium. 
As for pathophysiological functions, it is wide-
ly accepted that EAT should be considered as 
a  source of inflammatory mediators that might 
directly influence the myocardium and coronary 
arteries. In line with these observations, clinical 
studies suggested that EAT – through paracrine 
and vasocrine effects – may have an impact on 
the development and progression of coronary ath-
erosclerosis. In addition, an association between 
increased EAT and atrial fibrillation was also doc-
umented. The insulin resistance syndrome (the 
metabolic syndrome), type 2 diabetes, NAFLD and 
CAD proved to be associated with an increased 
amount of epicardial fat. Interestingly, accumu-
lation of EAT was also observed in patients with 
type 1 diabetes.
Treatment options for modifying EAT volume 
include lifestyle changes, bariatric surgery and 
using different drugs. Weight reduction in obese 
subjects may lead to a  decrease in EAT volume, 
while effects of different drugs on EAT are contro-
versial. Nevertheless, EAT should be considered as 
a new cardiovascular therapeutic target.
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